Sirolimus and Rapamycin for HCM in Cats and Dogs
A diagnosis of hypertrophic cardiomyopathy can leave owners asking whether a treatment might address the thickened heart muscle itself rather than only its complications. Sirolimus, also known as rapamycin, has attracted attention because it inhibits mTORC1, a signaling complex involved in cellular growth and pathological cardiac remodeling. In cats with subclinical, nonobstructive HCM, a randomized clinical trial found that delayed-release rapamycin reduced or limited progression of maximum left ventricular wall thickness over six months. The evidence is promising but narrowly defined. Sirolimus is not a cure, does not replace emergency treatment for congestive heart failure or arterial thromboembolism, and should not be used without veterinary assessment and monitoring. In the United States, a specific delayed-release sirolimus product has received conditional FDA approval for managing ventricular hypertrophy in cats with subclinical HCM; that approval does not extend to dogs, symptomatic heart failure, or every rapamycin formulation.
Why HCM thickens the heart
Hypertrophic cardiomyopathy is a disease of the heart muscle in which the left ventricular wall becomes abnormally thick. The thickening may involve the interventricular septum or the left ventricular posterior wall and may be symmetric or asymmetric. As the muscle thickens, the ventricle can become stiffer and less able to fill normally during diastole.
The myocardium may also develop cellular disorganization and interstitial fibrosis. These changes can affect relaxation, atrial pressure, electrical stability, and blood flow. Depending on disease stage, a cat may remain apparently well or develop left-sided congestive heart failure, arterial thromboembolism, or sudden death. The ACVIM consensus statement recommends classification and staging based on cardiac structure, function, clinical findings, and risk factors rather than applying one treatment to every cat.
Echocardiography is central to this assessment. Interventricular septal thickness in diastole, or IVSd, and left ventricular posterior-wall thickness in diastole, often reported as LVPWd, are among the measurements used to evaluate myocardial hypertrophy. They are interpreted alongside left atrial size, systolic function, outflow-tract obstruction, blood pressure, rhythm findings, biomarkers, and the animal’s clinical history.
A change in IVSd or LVPWd is therefore meaningful only in context. Measurement technique, imaging plane, loading conditions, examiner experience, and the presence of other diseases can all affect interpretation. A single wall-thickness value should not determine whether a cat starts or stops a cardiac medicine.
The mTORC1 mechanism
The mechanistic target of rapamycin, or mTOR, is a nutrient- and growth-sensitive signaling system involved in protein synthesis, metabolism, cell growth, and tissue remodeling. It forms two major complexes, mTORC1 and mTORC2, which have partly different roles in cardiovascular biology.
mTORC1 promotes anabolic processes that increase protein and lipid synthesis and can reduce autophagy, the process cells use to remove damaged proteins and organelles. Under chronic pathological stress, excessive mTORC1 activity may contribute to maladaptive cardiomyocyte growth and ventricular hypertrophy.
Rapamycin binds to an intracellular protein and inhibits mTOR signaling, with mTORC1 being particularly sensitive to short-term exposure. The proposed cardiac effect is a reduction in growth signaling that contributes to pathological remodeling. Experimental models and translational research have provided a rationale for studying whether this pathway can influence left ventricular hypertrophy in cats.
The mechanism remains a treatment hypothesis rather than a guarantee. mTOR signaling also supports normal biological functions, and prolonged or excessive pathway disruption may affect metabolism, immunity, or other organs. Sirolimus should therefore be understood as a carefully controlled therapy, not as a general-purpose supplement or a medication that can be safely shared between pets.
What the RAPACAT trial showed
The RAPACAT study was a double-blind, multicenter, randomized, placebo-controlled clinical trial involving 43 client-owned cats with subclinical, nonobstructive HCM. Cats were assigned to placebo, low-dose delayed-release rapamycin, or high-dose delayed-release rapamycin and were followed for six months. The study included serial echocardiography, blood pressure measurement, hematology, serum biochemistry, urinalysis, thyroid testing, cardiac biomarkers, and quality-of-life assessments.
At day 180, the study’s primary outcome—maximum left ventricular myocardial wall thickness at any measured location—was significantly lower in the low-dose group than in the placebo group. The reported comparison was statistically significant. A pooled comparison of both treatment groups with placebo also reached statistical significance. The study reported a significant treatment-related difference in maximum two-dimensional LVPWd when measurements were pooled across visits, while individual IVSd results did not show the same pattern.
The study included 43 cats at enrollment, but 36 completed all follow-up visits through day 180. Some cats were withdrawn because of congestive heart failure, sudden death, diabetic ketoacidosis, loss to follow-up, or other reasons. The investigators reported no statistically significant difference in the overall number of adverse events between groups during the study period, while also stating that additional studies were needed to confirm and further characterize the findings.
The result is best described as evidence that delayed-release rapamycin may prevent or delay progression of left ventricular hypertrophy in a specific population of cats. It is not evidence that rapamycin reverses every structural abnormality, prevents all cases of heart failure or thromboembolism, improves survival in every cat, or treats established acute HCM complications.
Formulation also matters. The study evaluated a delayed-release oral veterinary formulation, not every conventional sirolimus tablet, compounded preparation, or micro-emulsion product. Absorption, exposure, stability, dosing frequency, and safety cannot be assumed to be equivalent across formulations.
What changed in the regulatory picture
The evidence and regulatory position have developed since the original RAPACAT publication. In March 2025, the U.S. Food and Drug Administration conditionally approved Felycin-CA1, a delayed-release sirolimus tablet, for management of ventricular hypertrophy in cats with subclinical HCM. The FDA described it as the first product approved for use in cats with HCM for any indication.
The approval is specific. The FDA describes subclinical HCM in this context as ventricular hypertrophy without systemic hypertension, another compensatory cause of myocardial thickening, current or previous congestive heart failure, arterial thromboembolism, or severe left ventricular outflow-tract obstruction. The product is prescription-only, and the applicable product information includes restrictions relating to pre-existing liver disease and diabetes mellitus.
Conditional approval does not mean that every rapamycin product is interchangeable or that the medicine is approved for dogs. It also does not mean that sirolimus is intended to stabilize acute pulmonary edema, treat an arterial thromboembolism, or replace other medications selected for a cat’s clinical stage. Regulatory status can differ by country, so owners and clinicians should verify the applicable jurisdiction and product label.
Disease modification versus symptomatic care
Traditional HCM management is directed toward the animal’s phenotype and immediate risks. Depending on the patient, a veterinary cardiologist may consider treatment aimed at heart rate, diastolic filling, pulmonary congestion, systolic function, or arterial thromboembolism risk.
These approaches have different goals.
The distinction is especially important during deterioration. Breathing difficulty, open-mouth breathing, collapse, sudden hind-limb weakness, severe limb pain, pale or blue gums, or profound weakness can indicate a medical emergency. The owner should seek urgent veterinary care rather than waiting for sirolimus to act or changing the cardiac plan at home.
For owners organizing questions about monitoring and cardiovascular care categories, HERO Veterinary’s cardiovascular resources may provide general educational context. They are not a substitute for a veterinary prescription, echocardiogram, emergency assessment, or cardiology follow-up.
Safety monitoring is not optional
Before sirolimus is considered, the diagnosis and disease stage should be confirmed. The RAPACAT study excluded cats with several conditions, including clinically important outflow obstruction, systemic hypertension, hyperthyroidism, diabetes mellitus, significant renal dysfunction, moderate to severe anemia, congestive heart failure, previous arterial thromboembolism, or significant arrhythmias requiring treatment. Those exclusions illustrate why trial eligibility cannot be assumed from the word “HCM” alone.
A veterinarian may consider some combination of the following before and during treatment:
-
Echocardiography performed or interpreted by a veterinary cardiologist, including IVSd, LVPWd, maximum wall thickness, left atrial findings, systolic function, and outflow-tract assessment.
-
Complete blood count and serum biochemistry.
-
Blood pressure measurement, urinalysis, thyroid testing, and cardiac biomarkers when indicated.
-
Review of liver function, glucose status, kidney function, current medicines, supplements, and infection risk.
-
Repeat laboratory testing and echocardiography at intervals determined by the supervising veterinarian.
-
Therapeutic drug monitoring or other exposure assessment when clinically appropriate for the formulation and local protocol.
Sirolimus has immunosuppressive properties at higher exposures and can affect the gastrointestinal, hematologic, hepatic, renal, or metabolic systems. Potential concerns may include reduced appetite, vomiting, diarrhea, lethargy, cytopenias, infections, or laboratory abnormalities. A controlled trial’s overall safety result does not guarantee that an individual cat will tolerate treatment, particularly if the cat has concurrent disease or receives a different formulation.
Owners should contact the supervising veterinarian about persistent appetite loss, repeated vomiting or diarrhea, fever, unusual lethargy, recurrent infections, marked weakness, or other unexpected changes. Breathing difficulty, collapse, sudden paralysis or limb pain, or severe weakness requires emergency assessment rather than routine medication monitoring.
What the evidence means for dogs
The strongest clinical evidence is feline and stage-specific. RAPACAT studied cats with subclinical, nonobstructive HCM. It did not establish an equivalent benefit for dogs with HCM or other forms of canine myocardial hypertrophy.
A dog described as having a thickened ventricular wall may have a different underlying condition, such as systemic hypertension, endocrine disease, congenital disease, infiltrative disease, or another cardiomyopathy. A veterinarian must first determine whether the diagnosis is primary HCM and whether the feline evidence is relevant at all.
The same caution applies to medication selection. A cat product, feline label, or feline trial should not be extrapolated to a dog without specialist review. Species, formulation, body size, metabolism, disease mechanism, concurrent drugs, and monitoring requirements may differ substantially.
What to ask before treatment
A consultation should focus on whether the animal matches the studied or labeled population, not simply on obtaining a particular medicine. Useful questions include:
-
Is the diagnosis primary HCM, or could another condition explain the ventricular thickening?
-
Is the disease subclinical and nonobstructive?
-
Are there signs of congestive heart failure, left atrial enlargement, arterial thromboembolic risk, or significant arrhythmia?
-
Which echocardiographic values will be followed, including IVSd, LVPWd, maximum wall thickness, and left atrial measurements?
-
Is the proposed product the delayed-release formulation evaluated in feline studies or covered by the applicable product label?
-
Does the cat have liver disease, diabetes, kidney disease, hypertension, infection risk, or other conditions that affect suitability?
-
Which baseline and follow-up CBC, biochemistry, urine, blood-pressure, or cardiac-marker tests are required?
-
Which medicines must continue even if sirolimus is prescribed?
-
What symptoms require an emergency visit rather than a routine call?
A cardiologist may recommend observation and scheduled reassessment instead of immediate treatment, especially when a cat is stable and the expected benefit must be weighed against formulation-specific risks and monitoring demands. That approach reflects individualized evidence-based care rather than a failure to address the disease.
Frequently Asked Questions
Can sirolimus cure hypertrophic cardiomyopathy in cats? No. The available evidence does not show that sirolimus cures HCM. In a trial of cats with subclinical, nonobstructive HCM, delayed-release rapamycin affected the progression of maximum left ventricular wall thickness over six months, but it has not been shown to eliminate the disease or prevent every case of heart failure, thromboembolism, or sudden death.
How does rapamycin reduce heart-wall thickness in pets with HCM? Rapamycin inhibits mTORC1, a signaling complex involved in protein synthesis and cellular growth. The proposed effect is to reduce pathological hypertrophic remodeling, but the response depends on the species, diagnosis, disease stage, formulation, and veterinary monitoring.
Should I ask my vet to prescribe rapamycin if my cat was just diagnosed with subclinical HCM? You can ask whether your cat meets the clinical and regulatory criteria for a delayed-release sirolimus product, but treatment should not be assumed to be appropriate. The veterinarian may need to assess obstruction, blood pressure, liver function, diabetes status, concurrent disease, and the risk of future complications before making a decision.
What side effects should I watch for if a cat receives sirolimus therapy? Ask the supervising veterinarian about reduced appetite, vomiting, diarrhea, lethargy, fever, recurrent infections, unusual weakness, or abnormal laboratory results. Breathing difficulty, collapse, or sudden limb weakness requires emergency care rather than observation at home.